Shares of Aevi Genomic Medicine Inc (NASDAQ:GNMX) saw unusually-strong trading volume on Friday . Approximately 2,150,900 shares changed hands during mid-day trading, an increase of 8% from the previous session’s volume of 1,992,239 shares.The stock last traded at $0.18 and had previously closed at $0.17.
Separately, ValuEngine upgraded shares of Aevi Genomic Medicine from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st.
The stock has a market capitalization of $10.82 million, a P/E ratio of -0.36 and a beta of 0.72. The company’s 50-day moving average is $0.18 and its two-hundred day moving average is $0.20.
About Aevi Genomic Medicine (NASDAQ:GNMX)
Aevi Genomic Medicine, Inc, a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. The company's lead product candidates include AEVI-001, a glutamatergic neuromodulator, which has completed Phase II/III SAGA trial for the treatment of a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients who have genetic mutations that disrupt the mGluR network resulting in glutamate imbalance; and AEVI-002, an anti-LIGHT monoclonal antibody that is in Phase Ib clinical trial for use in severe pediatric onset Crohn's disease.
See Also: Are FAANG stocks a good investment?
Receive News & Ratings for Aevi Genomic Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aevi Genomic Medicine and related companies with MarketBeat.com's FREE daily email newsletter.